30-09-2026 07:20
via wallstreet-online.de
Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC
LUND, SE / ACCESS Newswire / September 30, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on …
Weiterlesen »
Analysten nachrichten
